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Propositions accompanying the PhD thesis: 
Antibody-free LC-MS/MS protein analysis of TRAIL 
1. Antibody-free LC-MS/MS will play a more important role in protein bioanalysis due to the 
increasing number of protein drugs currently in development. This will reduce the time needed 
for method development, which will reduce the amount of time needed for raising specific 
antibodies for ligand binding assays. This is currently a lengthy procedure that often has an 
uncertain outcome. (This thesis) 
2. LC-MS/MS protein analysis combined with SPE protein enrichment provides extensive 
multiplexing capabilities compared to ligand binding assays. This is beneficial for the screening 
of multiple closely related recombinant protein variants or combination therapies in clinical 
research. (This thesis) 
 
3. A systematic evaluation of antibody-free workflows is required in order to gain a better 
understanding of the relation between the physico-chemical properties of an analyte and its 
analytical behavior. (This thesis) 
 
4. Although a lot of knowledge about preparative-scale protein purification has been acquired over 
the years, this knowledge has still not been fully exploited for analytical-scale applications.  
(This thesis) 
 
5. Much knowledge about peptide enrichment can be derived from the vast amount of bioanalytical 
literature for small molecules. However, it is of importance to realize that the matrix is much 
more complex after digestion in comparison to the corresponding undigested sample.                       
(This thesis) 
 
6. The industry focuses on expressing and purifying biopharmaceutical proteins, but it should also 
focus on providing stable-isotope-labelled proteins as internal standards. This will largely 
improve the quality of the performed bioanalysis during the (pre-) clinical phase in drug 
research. (This thesis)   
 
7. A carefully optimized LC-MS/MS protein analysis method with the use of a proper internal 
standard can be validated according to the same current international guidelines used for the 
bioanalysis of small molecules. (This thesis) 
 
8. Due to the increasing drug prices, especially of biopharmaceuticals: “hand clapping of science is 
now inextricably linked to hand wringing over affordability” (New Eng J Med 2015; 373(19): 
1797-1799). Consequently, the demand for new biomarkers will strongly increase.   
 
9. The most exciting phrase to hear in science, the one that heralds new discoveries, is not 
‘Eureka!’ but ‘That’s funny’.  
Isaac Asimov 
 
10. Nothing is a waste of time if you use the experience wisely.  
Auguste Rodin 
